Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change
AbstractAgitation is a common and costly phenomenon associated with a number of psychiatric conditions including schizophrenia and bipolar disorder. Early identification and prompt intervention to relieve the symptoms of agitation are essential to avoid symptomatic escalation and emergence of aggressive behaviour. Recent consensus guidelines emphasise the need for non-coercive management strategies to protect the therapeutic alliance between patients and their healthcare providers —an alliance that is critical for the effective management of chronic psychiatric conditions. Rapid symptom relief and de-escalation of agitat...
Source: Drugs in R&D - February 5, 2019 Category: Drugs & Pharmacology Source Type: research
Should Cytochrome P450 Inducers be Used to Accelerate Clearance of Brodifacoum from Poisoned Patients?
AbstractA recent multi-state outbreak of life-threatening bleeding following inhalation of synthetic cannabinoids has been attributed to contamination with the long-acting anticoagulant rodenticide (LAAR) brodifacoum, a second-generation, highly potent, long-acting derivative of the commonly used blood thinner warfarin. While long-term treatment with high-dose vitamin K1 restores coagulation, it does not affect brodifacoum metabolism or clearance, and, consequently, brodifacoum remains in the human body for several months, thereby predisposing to risk of bleeding recurrence and development of coagulation-independent injury...
Source: Drugs in R&D - January 28, 2019 Category: Drugs & Pharmacology Source Type: research
Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon
ConclusionACTs are still effective and safe in Cameroon; however, there are insufficient data on their efficacy, safety and tolerability, therefore more RCTs should be conducted, including novel ACTs. (Source: Drugs in R&D)
Source: Drugs in R&D - January 17, 2019 Category: Drugs & Pharmacology Source Type: research
Assessment of Taste and Grittiness of Riomet ® ER Strawberry, Riomet ® ER Grape, Riomet ® Cherry, and Metformin Immediate-Release Tablets in Healthy Subjects
ConclusionsAll Riomet® formulations were significantly preferred overall to metformin IR crushed tablets. Both the strawberry and the grape flavors of Riomet® ER tended to be preferred to Riomet® Cherry. (Source: Drugs in R&D)
Source: Drugs in R&D - January 16, 2019 Category: Drugs & Pharmacology Source Type: research
Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
ConclusionsThis post-marketing analysis indicates that switching to silodosin from tamsulosin or naftopidil significantly improved symptoms associated with BPH, and silodosin was well tolerated in Japanese patients. (Source: Drugs in R&D)
Source: Drugs in R&D - January 3, 2019 Category: Drugs & Pharmacology Source Type: research
Suvorexant (Belsomra ® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey
ConclusionThis survey was an exploratory observational study without a control group; the interpretation of results may require the consideration of factors that may have caused bias in the results, such as demographic characteristics and effects of other drugs. However, the results suggest that suvorexant can be a useful drug in daily clinical practice for treating insomnia. (Source: Drugs in R&D)
Source: Drugs in R&D - December 14, 2018 Category: Drugs & Pharmacology Source Type: research
Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly
ConclusionsConcomitant perindopril + atorvastatin therapy demonstrated similar efficacy across all studies, with significant reductions in BP and achievement of target BP levels observed in a real-world setting. Results align with known safety profiles of atorvastatin and perindopril, with no unexpected AEs observed when compare d with data from treatment with the individual drugs. (Source: Drugs in R&D)
Source: Drugs in R&D - November 17, 2018 Category: Drugs & Pharmacology Source Type: research
Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
ConclusionThere was a high risk of bias across the 29 studies investigating conversion from MMF to EC-MPS for potential improvement in GI-related quality of life. The consolidated results of the three studies with low risk of bias suggest no evidence to convert patients stabilised on MMF. If a patient experiences GI-related adverse events whilst taking MMF, other methods should be explored before conversion to EC-MPS. (Source: Drugs in R&D)
Source: Drugs in R&D - November 13, 2018 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to Referees
(Source: Drugs in R&D)
Source: Drugs in R&D - November 8, 2018 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Budesonide in the Treatment of Eosinophilic Esophagitis: Updated Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies
ConclusionBudesonide showed significant effect at all treatment endpoints. However, since budesonide carries a risk of candidiasis and our inferences are based only on a small number of included studies, more research is warranted to clarify these results. (Source: Drugs in R&D)
Source: Drugs in R&D - November 2, 2018 Category: Drugs & Pharmacology Source Type: research
Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Na ïve Subjects with Type 2 Diabetes
ConclusionsThese results indicate that (1) body weight changes with canagliflozin were not associated with its glycemic efficacy; and (2) distinct glucose-lowering pathways may exist with canagliflozin, reducing insulin resistance in those who lose weight and enhancing β-cell function, as well as reducing insulin resistance, possibly via the decreased FFA levels, in those who do not lose weight. (Source: Drugs in R&D)
Source: Drugs in R&D - October 15, 2018 Category: Drugs & Pharmacology Source Type: research
Isavuconazole Kinetic Exploration for Clinical Practice
ConclusionsCollecting one blood sample just before the first maintenance dose to make an early estimation of the patient ’s most likely pharmacokinetic profile is one method of identifying patients with outlier pharmacokinetic behavior. (Source: Drugs in R&D)
Source: Drugs in R&D - October 10, 2018 Category: Drugs & Pharmacology Source Type: research
Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
DiscussionWarfarin and similar VKAs are standard therapy for patients with an MHV. Even with the appropriate use of therapy, the incidence of thromboembolic events is high at 1 –4% per year. Furthermore, bleeding risk is significant, ranging from 2 to 9% per year. The new frontier to be overcome in relation to use of the new oral anticoagulants is undoubtedly in patients with MHV. A significant portion of people with MHV worldwide will benefit if noninferiority of these new agents is confirmed.Trial RegistrationClinicalTrials.gov identifier:NCT03566303. Recruitment Status: Recruiting. First Posted: 25 June 2018. Last Upd...
Source: Drugs in R&D - October 6, 2018 Category: Drugs & Pharmacology Source Type: research
Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial
ConclusionsAlthough this was a small, exploratory trial that was not powered for significance, the reduction in surface volume observed in this study is noteworthy assuming that the natural course for untreated lesions is to maintain or increase in volume. Future studies are needed with larger study populations that incorporate longer durations of treatment and better standardization of volumetric measurements.Trial Registration ClinicalTrials.gov Identifier: NCT02332902 (Source: Drugs in R&D)
Source: Drugs in R&D - October 3, 2018 Category: Drugs & Pharmacology Source Type: research
